Glenmark Therapeutics, Inc.
Glenmark Therapeutics, Inc. appears in FDA public data with 1 recall, 0 510(k) clearances, 0 FDA inspections, and 0 compliance actions on record. Its most recent recall (D-0939-2023, Class II) was initiated on May 1, 2023.
Summary
- Total Recalls
- 1
- 510(k) Clearances
- 0
- Inspections
- 0
- Compliance Actions
- 0
Recent Recalls
| Number | Class | Product | Date |
|---|---|---|---|
| D-0939-2023 | Class II | Famotidine Tablets, USP, 20mg, 200-count bottle within a carton, Distributed by: Glenmark Therapeuti | May 1, 2023 |